DekaBank Deutsche Girozentrale Purchases 10,640 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

DekaBank Deutsche Girozentrale boosted its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 125.9% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 19,088 shares of the biotechnology company’s stock after purchasing an additional 10,640 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Aurinia Pharmaceuticals were worth $172,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. China Universal Asset Management Co. Ltd. grew its position in shares of Aurinia Pharmaceuticals by 352.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,613 shares of the biotechnology company’s stock worth $149,000 after purchasing an additional 12,940 shares in the last quarter. HighMark Wealth Management LLC grew its holdings in Aurinia Pharmaceuticals by 21.7% during the 4th quarter. HighMark Wealth Management LLC now owns 72,999 shares of the biotechnology company’s stock valued at $656,000 after buying an additional 13,000 shares in the last quarter. Compagnie Lombard Odier SCmA grew its holdings in Aurinia Pharmaceuticals by 8.7% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 25,000 shares of the biotechnology company’s stock valued at $225,000 after buying an additional 2,000 shares in the last quarter. SG Americas Securities LLC raised its position in shares of Aurinia Pharmaceuticals by 66.2% during the fourth quarter. SG Americas Securities LLC now owns 35,207 shares of the biotechnology company’s stock valued at $317,000 after buying an additional 14,025 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Aurinia Pharmaceuticals by 7.4% in the third quarter. Vanguard Group Inc. now owns 1,484,268 shares of the biotechnology company’s stock worth $11,533,000 after buying an additional 101,751 shares in the last quarter. 36.83% of the stock is owned by institutional investors.

Aurinia Pharmaceuticals Stock Performance

Shares of NASDAQ:AUPH opened at $5.00 on Wednesday. The firm has a fifty day simple moving average of $5.67 and a two-hundred day simple moving average of $7.32. The company has a quick ratio of 4.99, a current ratio of 5.50 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $723.10 million, a P/E ratio of -9.26 and a beta of 1.36. Aurinia Pharmaceuticals Inc. has a 52 week low of $4.85 and a 52 week high of $12.43.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). The company had revenue of $45.10 million for the quarter, compared to analysts’ expectations of $45.00 million. Aurinia Pharmaceuticals had a negative net margin of 44.45% and a negative return on equity of 20.10%. The company’s revenue for the quarter was up 58.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.18) earnings per share. On average, analysts expect that Aurinia Pharmaceuticals Inc. will post -0.06 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on AUPH. Royal Bank of Canada cut their target price on shares of Aurinia Pharmaceuticals from $13.00 to $8.00 and set an “outperform” rating for the company in a research note on Friday, February 16th. Jefferies Financial Group decreased their target price on Aurinia Pharmaceuticals from $9.50 to $9.00 and set a “hold” rating on the stock in a research report on Friday, February 16th. Cantor Fitzgerald dropped their price target on Aurinia Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Friday, February 23rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Friday, March 1st. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.